{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T20:28:43Z","timestamp":1768076923391,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Fresenius Kabi SwissBioSim"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40744-022-00432-1","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T06:02:45Z","timestamp":1646805765000},"page":"693-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects"],"prefix":"10.1007","volume":"9","author":[{"given":"Ahad","family":"Sabet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel S.","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia E.","family":"Kunina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Lucia","family":"Buccarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"432_CR1","unstructured":"EMC. Humira 40 mg\/0.4 ml pre-filled syringe and pre-filled pen. Summary of product characteristics (SmPC). 2021. https:\/\/www.medicines.org.uk\/emc\/medicine\/31860#gref. Accessed 8 Nov 2021."},{"key":"432_CR2","unstructured":"US FDA. HUMIRA\u00ae (adalimumab) injection, for subcutaneous use. 2021. https:\/\/www.rxabbvie.com\/pdf\/humira.pdf. Accessed 8 Nov 202l."},{"key":"432_CR3","unstructured":"EMC. Idacio 40 mg solution for injection in pre-filled pen. Summary of product characteristics (SmPC). 2021. https:\/\/www.medicines.org.uk\/emc\/product\/11307\/smpc#gref. Accessed 11 Feb 2021."},{"key":"432_CR4","unstructured":"EMA. Idacio \u2013 EPAR all authorised presentations. https:\/\/www.ema.europa.eu\/en\/documents\/all-authorised-presentations\/idacio-epar-all-authorised-presentations_en.pdf. Accessed 11 Feb 2021."},{"key":"432_CR5","unstructured":"Australian Government: Department of Health. Therapeutic Goods Administration: Idacio. 2020. https:\/\/www.tga.gov.au\/apm-summary\/idacio. Accessed 11 Feb 2021."},{"key":"432_CR6","unstructured":"New Zealand Government. New Zealand data sheet: Idacio 40 mg adalimumab (rch) solution for injection. 2020. https:\/\/www.medsafe.govt.nz\/Profs\/Datasheet\/I\/Idacioinj.pdf. Accessed 11 Feb 2021."},{"key":"432_CR7","unstructured":"Fresenius Kabi. Fresenius Kabi Canada launches IDACIO\u00ae (adalimumab injection) a biosimilar to HUMIRA\u00ae (adalimumab) for the treatment of multiple chronic inflammatory conditions. 2021. https:\/\/www.newswire.ca\/news-releases\/fresenius-kabi-canada-launches-idacio-r-adalimumab-injection-a-biosimilar-to-humira-r-adalimumab-for-the-treatment-of-multiple-chronic-inflammatory-conditions-822638421.html. Accessed 24 Feb 2022."},{"issue":"1","key":"432_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/19420862.2016.1259046","volume":"9","author":"L Magnenat","year":"2017","unstructured":"Magnenat L, Palmese A, Fremaux C, et al. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira\u00ae. MAbs. 2017;9(1):127\u201339.","journal-title":"MAbs"},{"issue":"4","key":"432_CR9","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/bcp.13039","volume":"82","author":"E Hyland","year":"2016","unstructured":"Hyland E, Mant T, Vlachos P, et al. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira\u00ae in healthy subjects. Br J Clin Pharmacol. 2016;82(4):983\u201393.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"432_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjd.18220","volume":"182","author":"J Hercogov\u00e1","year":"2020","unstructured":"Hercogov\u00e1 J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316\u201326.","journal-title":"Br J Dermatol"},{"issue":"12","key":"432_CR11","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1007\/s10067-019-04679-y","volume":"38","author":"CJ Edwards","year":"2019","unstructured":"Edwards CJ, Monnet J, Ullmann M, Vlachos P, Chyrok V, Ghori V. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis. Clin Rheumatol. 2019;38(12):3381\u201390.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"432_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s12325-018-0759-0","volume":"35","author":"N Maniadakis","year":"2018","unstructured":"Maniadakis N, Toth E, Schiff M, et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv Ther. 2018;35(9):1333\u201355.","journal-title":"Adv Ther"},{"issue":"8","key":"432_CR13","first-page":"859","volume":"23","author":"DT Rubin","year":"2017","unstructured":"Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017;23(8):859\u201367.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"432_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/10717544.2019.1587043","volume":"26","author":"BJF van den Bemt","year":"2019","unstructured":"van den Bemt BJF, Gettings L, Doma\u0144ska B, Bruggraber R, Mountian I, Kristensen LE. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019;26(1):384\u201392.","journal-title":"Drug Deliv"},{"issue":"10","key":"432_CR15","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.clinthera.2006.10.006","volume":"28","author":"A Kivitz","year":"2006","unstructured":"Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619\u201329.","journal-title":"Clin Ther"},{"key":"432_CR16","first-page":"1061","volume":"8","author":"W Demary","year":"2014","unstructured":"Demary W, Schwenke H, Rockwitz K, et al. Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience. Patient Prefer Adherence. 2014;8:1061\u201371.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"432_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/BOR.0000000000000591","volume":"31","author":"B Hsiao","year":"2019","unstructured":"Hsiao B, Fraenkel L. Patient preferences for rheumatoid arthritis treatment. Curr Opin Rheumatol. 2019;31(3):256\u201363.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"432_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1517\/14712590903530633","volume":"10","author":"J Borrs-Blasco","year":"2010","unstructured":"Borrs-Blasco J, Gracia-Prez A, Rosique-Robles JD, Caster MDE, Abad FJ. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. Expert Opin Biol Ther. 2010;10(3):301\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"432_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/03007995.2018.1560211","volume":"35","author":"J Ghil","year":"2019","unstructured":"Ghil J, Zieli\u0144ska A, Lee Y. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis. Curr Med Res Opin. 2019;35(3):497\u2013502.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"432_CR20","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/bcp.13245","volume":"83","author":"A Puri","year":"2017","unstructured":"Puri A, Niewiarowski A, Arai Y, et al. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab\/Humira, in healthy subjects. Br J Clin Pharmacol. 2017;83(7):1405\u201315.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"432_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40744-018-0119-1","volume":"5","author":"S Ramael","year":"2018","unstructured":"Ramael S, Van Hoorick B, Tiessen R, et al. Similar pharmacokinetics of the adalimumab (Humira\u00ae) biosimilar BI 695501 whether administered via subcutaneous autoinjector or prefilled syringe (VOLTAIRE\u00ae-AI and VOLTAIRE\u00ae-TAI): Phase 1, randomized, open-label, parallel-group trials. Rheumatol Ther. 2018;5(2):403\u201321.","journal-title":"Rheumatol Ther"},{"key":"432_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/PPA.S50583","volume":"8","author":"F Schwarzenbach","year":"2014","unstructured":"Schwarzenbach F, Trong MD, Grange L, et al. Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis. Patient Prefer Adherence. 2014;8:199\u2013209.","journal-title":"Patient Prefer Adherence"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00432-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00432-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00432-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T12:12:33Z","timestamp":1648555953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00432-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00432-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"assertion":[{"value":"22 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}